Challenge Theme – PAT

Filter:AllGeneralRegulatory NewsNewsletterExternalManufacturingPress ReleaseSkills and TrainingChallenge Theme – PATChallenge Theme – AAVChallenge Theme – iPSCsNon ClinicalCommercialisation of Research
Year:All2024202320222021 →
Braintree Manufacturing Innovation Centre: A case study in GMP transformational changeBraintree Manufacturing Innovation Centre: A case study in GMP transformational changeCGT Catapult establishing digital and automation testbeds to enable the scale-up of advanced therapy manufacturingCGT Catapult establishing digital and automation testbeds to enable the scale-up of advanced therapy manufacturingCell and Gene Therapy Catapult, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapiesCell and Gene Therapy Catapult, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapiesAutolomous and the Cell and Gene Therapy Catapult awarded £1.2m grant by UK Research and InnovationAutolomous and the Cell and Gene Therapy Catapult awarded £1.2m grant by UK Research and InnovationPress release: Cell and Gene Therapy Catapult opens new Process Analytical Technologies LaboratoryPress release: Cell and Gene Therapy Catapult opens new Process Analytical Technologies LaboratoryCGT Catapult concludes the Process Analytical Technologies (PAT) consortium aimed at improving ATMP bioprocessingCGT Catapult concludes the Process Analytical Technologies (PAT) consortium aimed at improving ATMP bioprocessingCGT Catapult Joins New Consortium to Advance Personalised Cell Therapy ManufacturingCGT Catapult Joins New Consortium to Advance Personalised Cell Therapy ManufacturingPress release: Cell and Gene Therapy Catapult brings together over 20 organisations with the aim to accelerate technology development and potentially lower cost in cell and gene therapy manufacturingPress release: Cell and Gene Therapy Catapult brings together over 20 organisations with the aim to accelerate technology development and potentially lower cost in cell and gene therapy manufacturing